Terns PharmaceuticalsTERN
TERN
About: Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
Employees: 66
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
121% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 24
96% more call options, than puts
Call options by funds: $8.73M | Put options by funds: $4.45M
48% more capital invested
Capital invested by funds: $449M [Q2] → $662M (+$214M) [Q3]
41% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 37
23% more funds holding
Funds holding: 126 [Q2] → 155 (+29) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
7.78% less ownership
Funds ownership: 101.92% [Q2] → 94.14% (-7.78%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7.50
28%
upside
Avg. target
$15.83
170%
upside
High target
$20
241%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
JMP Securities Silvan Tuerkcan 35% 1-year accuracy 18 / 51 met price target | 241%upside $20 | Market Outperform Reiterated | 4 Dec 2024 |
HC Wainwright & Co. Ed Arce 54% 1-year accuracy 79 / 146 met price target | 28%upside $7.50 | Neutral Reiterated | 4 Dec 2024 |
Oppenheimer Jay Olson 20% 1-year accuracy 20 / 102 met price target | 241%upside $20 | Outperform Maintained | 4 Dec 2024 |
Financial journalist opinion
Based on 3 articles about TERN published over the past 30 days
Positive
Market Watch
2 weeks ago
Terns's stock soars as analysts cheer leukemia data — and predict more gains
The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill.
Positive
Market Watch
2 weeks ago
Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial
Terns Pharmaceuticals Inc.'s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia.
Neutral
GlobeNewsWire
2 weeks ago
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of December 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”).
Positive
Benzinga
1 month ago
Top 3 Health Care Stocks You'll Regret Missing In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
GlobeNewsWire
1 month ago
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience
Negative
Market Watch
1 month ago
RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr. his pick to head the Department of Health and Human Services.
Neutral
GlobeNewsWire
2 months ago
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns.
Positive
Seeking Alpha
2 months ago
Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
Terns Pharmaceuticals is developing TERN-601, an oral GLP-1R agonist, which showed a placebo-adjusted weight loss of 4.9% in a phase 1 trial for obesity treatment. The company plans to initiate a phase 2 study for TERN-601 in 2025, creating a significant catalyst opportunity for investors. The company is also developing TERN-701 for chronic myeloid leukemia, with interim phase 1 data expected in December 2024, offering another investment opportunity.
Positive
The Motley Fool
3 months ago
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill. The results looked better than those from a key rival.
Positive
The Motley Fool
3 months ago
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Viking Therapeutics isn't the only weight loss biotech out there. Terns Pharmaceuticals just published some good phase 1 clinical trial data.
Charts implemented using Lightweight Charts™